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Previous studies have shown that dopamine D1 receptor antagonists impair novel object recognition
memory but the effects of dopamine D1 receptor stimulation remain to be determined. This study
investigated the effects of the selective dopamine D1 receptor agonist SKF81297 on acquisition and
retrieval in the novel object recognition task in male Wistar rats. SKF81297 (0.4 and 0.8 mg/kg s.c.)
given 15 min before the sampling phase impaired novel object recognition evaluated 10 min or 24 h
later. The same treatments also reduced novel object recognition memory tested 24 h after the
sampling phase and when given 15 min before the choice session. These data indicate that D1
receptor stimulation modulates both the encoding and retrieval of object recognition memory.
Microinfusion of SKF81297 (0.025 or 0.05 μg/side) into the prelimbic sub-region of the medial
prefrontal cortex (mPFC) in this case 10 min before the sampling phase also impaired novel object
recognition memory, suggesting that the mPFC is one important site mediating the effects of D1
receptor stimulation on visual recognition memory.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
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Delacour, 1988). As this is an innate tendency, novel object
recognition (NOR) procedures offer advantages over many
learning and memory tasks in that NOR can be studied
without training or the use of positive (e.g. food) or
negative (e.g. foot shock) reinforcers (Lyon et al., 2012).
Furthermore by selecting an appropriate phase for drug
injection, the task can be utilised to distinguish effects on
acquisition, consolidation and/or retrieval of visual memory
(King et al., 2004).
The neurobiological substrates of recognition memory
have been extensively studied (Winters et al., 2008;
Warburton and Brown, 2010) and shown to require plasticity
within the perirhinal cortex (Bussey et al., 1999; Brown and
Aggleton, 2001). The prefrontal cortex (PFC) is also criti-
cally involved in object discrimination. While lesions to the
medial prefrontal cortex (mPFC) particularly impair recog-
nition memory requiring judgement about recency and
object location (Hannesson et al., 2004), there is also an
evidence that prefrontal mechanisms contribute to NOR
based simply on object identity in rats. Recent fMRI studies
show that disruption of mPFC activation is correlated with
the extent of reduction in recognition memory (Zanto et al.,
2011). Furthermore lesions of the mPFC in rats reduced
memory for visual objects (Ragozzino et al., 2002), while
anterior cingulate lesions in monkeys similarly impaired
object memory processes including NOR (Meunier et al.,
1997). In addition, electrophysiological recordings in the
PFC have shown different patterns of neuronal activation
dependent on the familiarity of the objects (Xiang and
Brown, 2004).
It is also well established that dysfunction of dopamine
(DA) neurotransmission disrupts recognition memory. For
example, both acute and subchronic injection of the DA
releasing agent, methamphetamine reduced NOR (Belcher
et al., 2008; Camarasa et al., 2010). The mPFC is innervated
by dopaminergic projections from the ventral tegmental
area (VTA) (Lindvall et al., 1974) and we have previously
shown that bilateral microinjection of the selective DA D3
receptor antagonist, S33084, into the PFC of rats caused a
dose-related (0.025 or 0.05 μg/side) improvement, while
injection of the preferential D2 receptor antagonist,
L741,626, into the same region caused a dose-related
(0.025 or 0.05 μg/side) impairment in NOR (Watson et al.,
2012a, 2012b). While it is well established that DA D1
receptor modulation in the mPFC alters working memory
(Goldman-Rakic, 1998), questions remain concerning its role
in recognition memory. Besheer et al. (1999) reported that
systemic administration of the D1 receptor antagonist,
SCH23390 impaired NOR. Further studies suggest that D1
receptor activity in the mPFC is important for both the
consolidation (Nagai et al., 2007; Rossato et al., 2013) and
retrieval of long term recognition memory (Hotte et al.,
2006). However, whether D1 receptor activation may also
inﬂuence the acquisition of NOR has yet to be determined.
Therefore, the present study used systemic administra-
tion of the selective D1 receptor full agonist, R/S-(+/)-6-
chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-
benzazepine (SKF81297; Ki=2.2 nM; D1/D2 ratio 4454.5,
Nielsen et al., 1989), to explore the effect of D1 receptor
stimulation on the encoding and expression of recognition
memory after a short (10 min) and a long inter-trial intervaldelay (24 h). Second microinjection of SKF81297 into the
prelimbic (PL) part of the mPFC prior to the acquisition of
object memory was performed to determine whether short
term recognition memory was dependent on mPFC DA D1
receptor activation.
2. Experimental procedures
2.1. Animals
Adult male Wistar rats (Charles River, UK) were caged in group of
four on a 12:12 h light/dark cycle with food and water ad libitum.
Rats were handled for approximately 10 min per day for 1 week
prior to any procedure. All procedures were carried out in
accordance with the United Kingdom (UK) Animals Scientiﬁc
Procedures Act 1986, Project Licence number: PPL 40/3163. In
experiments 1 (n=36), 2 (n=35), 3 and 5 (n=36), non-naive rats
(mean weight 431 g) were used, in each case counterbalanced for
previous experimental experience. In experiments 4 and 6, 11 naive
rats (mean weight 297 g; operated in the range 270–340 g) were
used. One rat was excluded from the analysis because it escaped
from the NOR box during both the sampling and choice phase.
2.2. Systemic injection procedure
In experiments 1 and 2, saline or the selective D1 agonist SKF81297
(0.4 or 0.8 mg/kg s.c.) was injected 15 min before the sampling
phase of the NOR procedure (see below). In experiments 3 and 5,
the same doses were administered 15 min before the NOR testing
phase and immediately prior to exposure to the locomotor activity
boxes respectively. Drug doses were those used in a previous study
in our laboratory (Nelson et al., 2012). SKF81297 hydrobromide
(Tocris, UK) was dissolved in saline (0.154 M sterile NaCl) on each
test day with the pH adjusted to 7 using 0.1 M NaOH.
2.3. Implantation of guide cannulae into the mPFC
Rats (n=11) were implanted with bilateral infusion guide cannula
consisting of a 5 mm plastic pedestal holding two 26 gauge metal
tubes 1.2 mm apart and projecting 4.5 mm from the pedestal was
implanted through small holes drilled in the skull. The tips of the
guide cannula were aimed 0.5 mm above the injection site in the PL
part of the prefrontal cortex, at the following coordinates (Paxinos
and Watson, 1998): 3 mm anterior, 70.6 mm lateral from bregma
and 3.8 mm ventral from the skull surface. For additional informa-
tion see Supplementary material.
2.4. Microinjection procedure
Rats were gently restrained and 33 gauge injectors (Plastic Ones,
Bilaney, UK) inserted into the guides such that tips extended 0.5 mm
into the mPFC, and the injector ends were connected through
polyethylene tubing to 5-ml syringes mounted on a microinfusion
pump (model SP200iZ, World Precision Instruments). A volume of
0.5 μl/side of 0.154 M saline or SKF81297 (0.025 or 0.05 μg/side) was
then infused bilaterally over 1 min. The movement of an air bubble,
which was included in the tubing, was monitored to verify that liquid
was successfully infused into the brain. The injector remained in
place for one additional minute to allow for tissue absorption of the
infusion bolus. The injectors were then removed and the stylets
replaced. The choice phase of novel object discrimination (NOD)
commenced 10 min after infusion. Locomotor testing began as soon
as possible after the infusion and the time course of activity was
followed for 60–90 min to determine the optimal onset of the drug
action. In experiments 4 and 5b, SKF81297 used was dissolved in
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aliquoted and kept frozen until use. On the day of infusion an
aliquot was thawed and a part of this solution was diluted to a
concentration of 0.025 μg/0.5 μl with saline.
2.5. NOR: behavioural apparatus
All testing was conducted in a 38 40 cm opaque plastic rectan-
gular arena with 54 cm high walls. The stimuli consisted of
duplicate copies of bottles and ﬂasks made of glass, metal or
plastic of varied shape, colour and size which were too heavy to be
displaced by the animal (Ennaceur and Delacour, 1988), for more
information also see Supplementary material. The rats' behaviour
was recorded and later analysed.
2.6. NOR: behavioural procedure
The NOR task was based on previously established protocols (Nelson
et al., 2010, 2011). One day before the test day, animals received
an acclimatisation session. The rats were placed individually into
the arena for 1 h. On the following day, rats underwent a re-
acclimatisation of 3 min to the arena. In experiments 1, 2 and 3,
different groups of rats were injected with saline, 0.4 or 0.8 mg/kg
of SKF81297 (s.c.) and returned to their home cage for 15 min. The
rats were then given one 5 min sample phase in which the animals
were allowed to explore two identical copies of the sample object.
In experiment 3, rats were exposed to 5 min sample phase directly
after the re-acclimatisation. The total time spent exploring the two
identical objects was recorded. After a delay of 10 min (experiment
1) or 24 h (experiments 2 and 3), in which rats were return to their
home cage, each rat was replaced for 3 min in the arena, which now
contained a novel object and an identical copy of the object
previously seen during the sampling phase. In every experiment, at
the sampling phase the object exploration time was scored as the
total over the full 5 min exposure to the objects. For the choice
sessions, the time spent exploring the familiar and novel object was
recorded over a total of 3 min. Because the preference for novel
object, objects can decline rapidly, these exploration times were
scored in three 1-min blocks.
Comparison between the systemic drug studies (experiments 1–3)
provides the temporal resolution to distinguish effects at encoding
versus retrieval in the NOR procedure. Since both encoding and
retrieval were affected, the experiment 4 infusion study used the
experiment 1 timeline (infusion before the sample phase and a
10 min retention interval) which does not distinguish effects on
encoding and retrieval. Experiment 4 was run over a 6 day cycle in a
within-subjects design to reduce the number of animals subjected
to the cannulation procedure. On days 1, 3 and 5 rats were placed
individually into the arena for 1 h. On days 2, 4 and 6, rats
underwent a re-acclimatisation of 3 min to the arena before
receiving one of three bilateral mPFC infusions 10 min before the
sampling phase: saline, 0.05 μg (0.025 μg/side), 0.1 μg (0.05 μg/
side) of the selective D1 receptor agonist SKF81297. The order of
the three infusions was counterbalanced using a Latin square
design. During the 5 min sampling period the rats were exposed
to two identical objects. After a delay of 10 min in which the rats
were returned to their home cage, each rat was tested for 3 min in
the arena containing a novel object and an identical copy of the
object previously seen during the sampling phase. Again, the time
spent exploring the familiar and novel object was recorded. In the
course of the three sampling/choice sessions, three different object
pairs were used, counterbalanced across the infusions conditions.
2.6.1. Inter-rater reliability
An independent experimenter who was blind to the treatment and
object contingencies rescored 20% of all test phases from theoriginal video recording. The rescored results signiﬁcantly corre-
lated with the original scores (r=0.85, po0.0001) indicating robust
inter-rater reliability.
2.7. Locomotor activity: behavioural apparatus
Locomotor activity was assessed as described by Pezze et al. (2014),
and in the Supplementary material.
2.8. Locomotor activity: experimental designs
The locomotor effects of SKF81297 were tested in between-
subjects designs. One day before the injection or infusion each
rat was placed in a test chamber for 1 h, to obtain baseline
measures of activity, and also to habituate the animal to the box.
These baseline measures of activity were used to match activity
levels across the injection or infusion group allocations for the
subsequent tests of the locomotor effects of SKF81297. On the
following day, rats were replaced in the same test chamber for
30 min to achieve further habituation and so maximise the ability to
detect any SKF81297-induced locomotor hyperactivity. Rats were
then subcutaneously injected with saline, 0.4 or 0.8 mg/kg of
SKF81297 in experiment 5, or microinfused with saline, 0.025 or
0.05 μg/side into the mPFC in experiment 6, and immediately
replaced in the activity box for 60 min.
2.9. Veriﬁcation of cannulae placements for
behavioural studies
Histology was assessed as described by Pezze et al. (2014), and in
the Supplementary material.
2.10. Design and analysis
The results are shown as means (7SEM); p Values of less than 0.05
are considered to indicate statistical signiﬁcance.
2.10.1. Exploration time
In experiments 1–3, choice exploration times were analysed in a
mixed design using treatment as the between-subjects factors.
Object (novel versus familiar) was a within-subjects factor as was 1-
min block (at 3 levels). Thus, this design examines minute-by-
minute variation in NOR over the duration of the test session. The
results obtained using the Latin Square procedure of experiment
4 were analysed in an entirely within-subjects design, in the same
way as experiments 1–3 but in this case treatment was also within-
subjects. ANOVAs showed marked variation in NOR over the 3 min of
test (as reﬂected in signiﬁcant interactions between object and 1-
min block). Therefore, based on the results obtained in experiments
1 which consistently indicated that the preferential object explora-
tion was greater in the ﬁrst min of the choice trial, follow up
analyses were restricted to the ﬁrst min. Where ANOVA showed
signiﬁcant interactions, separate follow-up analyses of the familiar
or novel object exploration time were performed using treatment
as the factor. Post-hoc pairwise comparisons were performed using
Fisher's PLSD. On the basis of the pattern of results of the ﬁrst
experiment, planned comparisons requiring a paired comparisons t-
tests were systematically used to test for NOD.
2.10.2. Discrimination ratio
The time spent exploring the novel object divided by the total time
spent exploring both objects was calculated for the ﬁrst min and
total three min of exploration. In experiment 1–3 the data were
subjected to ANOVA with drug treatment as a between-subjects
factor. In experiment 4 drug treatments was a within-subject factor.
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PLSD test. One sample t-tests were used to compare performance
measures to the 0.5 value of the ratio which reﬂects chance level
performance.
2.10.3. Locomotor activity
In experiments 5 and 6 the activity levels were examined in a mixed
design with doses as the between-subjects factor and 10 min blocks
(locomotor activity) as the within-subjects factor.
3. Results
3.1. Experiment 1: spontaneous NOR after a delay
of 10 min – systemic injection of SKF81297 before
the sampling phase
ANOVA showed that SKF81297 attenuated the total exploration
of both objects during both the sample (F(2,33)=15.81;
po0.0001) and choice phases (F(2,33)=6.17; po0.006) of
the NOD test when given by systemic administration (Table 1).
Post-hoc analysis showed that both doses of SKF81297, 0.4 and
0.8 mg/kg, signiﬁcantly reduced the total object exploration
time during the sample phase (po0.01 and po0.001 from
saline, respectively) and the highest dose reduced exploration
during the choice phase (po0.05) (Table 1).
A minute by minute change in object exploration over the
3 min test period of the choice trial was revealed by a
three-way interaction of treatment object 1-min block
(F(4,66)=2.89; po0.029). Inspection of the means indi-
cated that the effect of SKF81297 was due to a decrease of
the time spent exploring the novel object during the ﬁrstTable 1 Effect of systemic injection or mPFC microinfusion of
both objects, during the sample (a), and choice (b) phases of a
Injections Delay Sa
Systemic before encoding 10 min a
70
b
43
Systemic before encoding 24 h a
37
b
30
Systemic before test session1 24 h a
26
b
24
Infusions Delay Sa
In mPFC before encoding 10 min a
56
b
40
npo0.05;
nnpo0.001;
nnnpo0.0001:signiﬁcant decreases in the time spent exploring the
1Note: where drug administration was systemic before test session
by drug condition-to-be, for comparison.minute of the choice trial (Fig. 1A). ANOVA of exploration
time during the ﬁrst 1-min block yielded a signiﬁcant
interaction of object treatment (F(2,33)=8.49;
po0.002). This interaction was however not signiﬁcant
during the second (F(2,33)=0.79; p=0.46) and the third
(F(2,33)=1.34; p=0.27) 1-min blocks.
Follow-up analyses of the time spent exploring the novel
object during the ﬁrst 1-min block also showed a main
effect of drug (F(2,33)=7.55; po0.002). This arose because
of decreased novel object exploration compared to saline
after both low (sal vs. 0.4 mg/kg po0.05) and high doses
(sal vs. 0.8 mg/kg po0.05) of SKF81297. There was no
signiﬁcant effect of drug on familiar object exploration (F
(2,33)=1.32; p=0.28). Furthermore, planned comparison
(by paired t-test) showed that the exploration times during
the ﬁrst 1-min block were signiﬁcantly higher for the novel
object than for the familiar object in the control group (t
(11)=15.12; po0.0001) and after an injection of 0.8 mg/kg
of SKF81297 (t(11)=2.85; po0.05), but not after injection
of 0.4 mg/kg (t(11)=1.52; p=0.15) (Fig. 1B).
It was also clear from the discrimination ratios that during
the ﬁrst 1-min block the drug groups differed markedly in the
proportion of time spent exploring the two objects (Fig. 1B).
ANOVA of the 1 min discrimination ratio conﬁrmed a signiﬁcant
main effect of SKF81297 (F(2,32)=3.82; po0.04). Post-hoc
comparisons indicated that the lower (po0.05), but not the
higher dose (p=0.16) of SKF81297, decreased recognition of
the novel object compared to saline. This was also conﬁrmed
by one sample t-tests comparing the discrimination ratio in
each group to chance (0.5). Performance differed from chance
in the saline group (t(11)=11.29; po0.0001) and the groupSKF81297 on exploration time in seconds (mean+S.E.M.) of
NOR task.
l 0.4 mg/kg 0.8 mg/kg
.177.3 36.274.8 nn 24.875.2nnn
.673.3 33.575.0 24.073.1n
.675.5 20.674.8n 18.673.4n
.672.2 26.573.4 26.772.5
.677.7 23.271.7 29.575.1
.273.1 7.571.6nnn 7.271.4 nnn
l 0.025 lg/side 0.05 lg/side
.374.1 45.075.2 56.178.4
.474.3 25.473.9n 33.474.6
objects compared to saline (sal).
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Figure 1 Effect of saline (sal) or SKF81297 (0.4 and 0.8 mg/kg)
injected before the sample phase on novel object recognition after
a retention delay of 10 min. (A) Timeline of experiment 1 to
illustrate the 10 min retention delay between the sample and the
choice phase and the timing of the injections 15 min before the
sample phase. (B) Effect of SKF81297 on the ﬁrst min of exploration
of a novel (Nov) and a familiar (Fam) object during the choice
phase. *po0.05, ***po0.0001, signiﬁcant difference as compared
to familiar object. (C) Choice performance presented as discrimi-
nation ratio; stippled line indicates chance. **po0.001, signiﬁ-
cantly different from the saline group; #po0.05, ###po0.0001
signiﬁcantly different from chance. Data are shown as a mean7S.
E.M (n=12 rats per group).
2149Dopamine D1 receptor stimulation modulatesreceiving 0.8 mg/kg (t(11)=3.23; po0.05), but not in the
group receiving an injection of 0.4 mg/kg of SKF81297 (t(10)
=0.70; p=0.49).
These data indicate that systemic activation of D1 receptor
before encoding impaired the ability of the rats to discriminate
novel from familiar object using a trial delay of 10 min.3.2. Experiment 2: spontaneous NOR after a delay
of 24 h – systemic injection of SKF81297 before the
sampling phase
In this experiment, SKF81297 affected exploration time
during the sample (F(2,13)=5.10; po0.03) but not thechoice (F(2,13)=0.32; p=0.73) phase after systemic admin-
istration before object encoding (Table 1). Post-hoc analysis
showed that both doses of SKF81297 signiﬁcantly reduced
the total object exploration time during the sample phase
(sal vs. 0.4 mg/kg po0.05 and sal vs 0.8 mg/kg po0.05).
There was no interaction between object, drug and 1-min
block (F(4,64)=1.53; p=0.20). However, there was a main
effect of object (F(1,32)=9.80; po0.004) reﬂecting a
preferential exploration of the novel object and a main
effect of 1-min block (F(2,64)=47.52; po0.0002), consis-
tent with greater exploration of the novel object during the
ﬁrst min (F(1,32)=8.32; po0.007) but not during the
second (F(1,32)=3.57; p=0.06) and third minutes (F(1,32)
=0.07; p=0.79). Accordingly, and for comparison with
experiment 1, planned comparisons of the novel versus
familiar object were restricted to the ﬁrst minute only.
These showed that rats in the saline group explored the
novel object (t(11)=2.79; po0.05) more than rats injected
with 0.4 mg/kg (t(10)=1.06; p=0.31) and 0.8 mg/kg (t(11)
=1.08; p=0.30) SKF81297 conﬁrming that the main effect
of SKF81297 was restricted to early exploration (Fig. 2A).
The discrimination ratio during the ﬁrst 1-min of testing
showed SKF81297 treated rats explored both objects
equally, whereas the saline group tended to show a pre-
ference for the novel object (Fig. 2B). Even though there
was no signiﬁcant effect of drugs on the discrimination ratio
during the 1-min block (F(2,32)=0.57, p=0.56) only the
performance of the control group was better than chance (t
(11)=3.23; po0.05).
These data indicate that systemic activation of the D1
receptor transmission before the encoding tended to impair
the recognition of a novel object after a delay of 24 h.3.3. Experiment 3: spontaneous NOR after a delay
of 24 h – systemic injection of SKF81297 before the
choice phase
The groups were well matched for exploration time during
the sample phase (F(2,33)=0.815; p=0.45) but exploration
was decreased under SKF81297 during the choice phase (F
(2,33)=19.19; po0.0001) (Table 1). Post-hoc analysis
showed that both doses of SKF81297 signiﬁcantly reduced
the total object exploration time during the 3 min choice
phase (sal vs. 0.4 mg/kg po0.05 and sal vs. 0.8 mg/kg
po0.05).
A signiﬁcant interaction between treatment object 1-
min block (F(4,66)=3.38; po0.02) suggests that the effects
on object exploration changed over the 3 min of the choice
trial. Examination of the means conﬁrmed that NOR was
again more marked during the ﬁrst minute of exploration
(Fig. 3A) and prompted further analysis by each 1-min
block. ANOVA of exploration time during the ﬁrst 1-min
block yielded a signiﬁcant interaction of object treatment
(F(2,33)=7.40; po0.003), suggesting that the drug prefer-
entially reduced novel object exploration time. This inter-
action was not signiﬁcant during the second (F(2,33)=0.84;
p=0.44) and the third (F(2,33)=0.47; p=0.63) 1-min
blocks.
Follow-up analysis of the time spent exploring the novel
object during this ﬁrst 1-min block showed that both 0.4 (sal
vs. 0.4 mg/kg po0.0001) and 0.8 mg/kg (sal vs. 0.8 mg/kg
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Figure 3 Effect of saline (sal) or SKF81297 (0.4 and 0.8 mg/kg)
injected before the choice phase on novel object recognition
after a retention delay of 24 h. (A) Timeline of experiment 3 to
illustrate the 24 h retention delay between the sample and the
choice phase and the timing of injections 15 min before the
choice phase. (B) Effect of SKF81297 on the ﬁrst min of
exploration of a novel (Nov) and a familiar (Fam) object during
the choice phase. ***po0.0001, signiﬁcant difference com-
pared to familiar object. (C) Choice performance presented
as discrimination ratio; stippled line indicates chance.
#po0.05, signiﬁcantly different from chance. Data are shown
as a mean7S.E.M (n=12 rats per group).
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Figure 2 Effect of saline (sal) or SKF81297 (0.4 and 0.8 mg/kg)
injected before the sample phase on novel object recognition
after a retention delay of 24 h. (A) Timeline of experiment 2 to
illustrate the 24 h retention delay between the sample and the
choice phase and the timing of injections 15 min before the
sample phase. (B) Effect of SKF81297 on the ﬁrst min of
exploration of a novel (Nov) and a familiar (Fam) object during
the choice phase.*po0.05, signiﬁcant difference compared to
familiar object. (C) Choice performance presented as discrimi-
nation ratio; stippled line indicates chance. #po0.05, signiﬁ-
cantly different from chance. Data are shown as a mean7S.E.M
(n=11-12 rats per group).
M.A. Pezze et al.2150po0.0001) of SKF81297 decreased novel object exploration
time. While there was also a signiﬁcant effect of drug on
familiar object exploration (F(2,33)=5.04; po0.02), this
effect only reached signiﬁcance after injection of 0.4 mg/kg
SKF81297 (sal vs. 0.4 mg/kg po0.05; sal vs. 0.8 mg/kg
p=0.07). Planned comparisons demonstrated that the
exploration times were signiﬁcantly higher for the novel
than the familiar object in the control group (t(11)=3.93;
po0.001), but not after 0.4 mg/kg (t(11)=1.63; p=0.13) or
0.8 mg/kg of SKF81297 (t(11)=1.51; p=0.15) (Fig. 3A).Both doses of SKF81297 tended to reduce the discrimina-
tion ratio compared to saline during the ﬁrst 1-min of the
choice trial (Fig. 3B) but there was no signiﬁcant effect of
drug (F(2,32)=1.43, p=0.25), However, planned compar-
ison showed that performance in the saline-injected control
group was greater than chance (t(11)=4.23; po0.05),
whereas it was not with either 0.4 mg/kg (t(10)=0.4;
p=0.69) or 0.8 mg/kg (t(11)=0.11; p=0.91) of SKF81297.
Thus these data suggest that the retrieval of NOR is also
disrupted by DA D1 receptor stimulation.
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Figure 4 Effect of saline (sal) or SKF81297 (0.025 and 0.05 μg/
side) infused into the prelimbic cortex before the sample phase
on novel object recognition after a retention delay of 10 min.
(A) Timeline of experiment 4 to illustrate the 10 min retention
delay between the sample and the choice phase, the timing of
the infusions 15 min before the choice phase and the repeated
( 3) testing in the within-subjects design. (B) Effect of
SKF81297 on the ﬁrst min of exploration of a novel (Nov) and
a familiar (Fam) object during the choice phase. *po0.05,
**po0.001, signiﬁcant difference as compared to the familiar
object. (C) Choice performance presented as discrimination
ratio; stippled line indicates chance. *po0.01, signiﬁcantly
different from the saline group; #po0.05, signiﬁcantly differ-
ent from chance. Data are shown as a mean7S.E.M (n=10 rats
in total).
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of 10 min – mPFC infusion of SKF81297 before the
sampling phase
ANOVAs of the time spent exploring both objects did not
reveal any differences between groups during the sample
phase (F(2,18)=1.42; p=0.26) but showed a reduction in
total exploration during the choice phase (F(2,18)=4.86,
po0.03) with injection of SKF81297 into the mPFC (Table 1).
Post-hoc analysis revealed that only the lower dose reduced
exploration during the choice phase (sal vs. 0.025 μg/side
po0.05 and sal vs. 0.05 μg/side p=0.16; Table 1).
There was a 3 way interaction of treatment object 1-
min block in the linear trend (F(1,9)=7.37; po0.03). Fig. 4B
shows that intra-mPFC infusion of SKF81297 decreased novel
object preference during the ﬁrst minute of the choice
phase. Accordingly follow-up analyses were restricted to
the ﬁrst 1 min where ANOVA showed a very strong trend of
object treatment (F(2,18)=3.50; p=0.05) while novel
object preference in the 2-min (F(2,18)=1.62; p=0.22) and
3-min blocks (F(2,18)=0.49; p=0.95) was unaffected. Ana-
lysis of the 1 min novel and familiar object exploration times
separately showed a main effect of drug (F(2,18)=4.64;
po0.03). Furthermore novel object exploration time was
decreased compared to the saline group after mPFC-infusion
of SKF81297 at 0.025 μg/side (po0.05) and 0.05 μg/side
(po0.05). On the contrary, the exploration time of the
familiar object was unaffected by this treatment (F(2,18)
=1.62; p=0.22). Planned comparisons demonstrated that the
exploration times between the novel and the familiar object
were signiﬁcantly different in the saline group (t(9)=5.94;
po0.001) and after an infusion of 0.025 μg/side of SKF81297
(t(9)=2.40; po0.05). However at 0.05 μg/side, there was no
difference (t(9)=0.80; p=0.44) (Fig. 4A).
The discrimination ratio analysis for the ﬁrst 1-min block
also yielded a signiﬁcant main effect of dose (F(1,9)=8.87;
po0.002). Post-hoc comparisons revealed a signiﬁcant
decrease in performance after infusion of 0.05 μg/side of
SKF81297 compared to the control group (sal vs. 0.025 μg/
side po0.05; sal vs. 0.05 μg/side p=0.16) (Fig. 4C). Addi-
tional evidence from one sample t-tests showed that only the
performance of the saline group was different from chance
(chance vs. saline t(9)=6.92; po0.0001; chance vs. 0.025 μg/
side t(9)=1.29; p=0.23; chance vs. 0.05 μg/side t(9)=0.18;
p=0.86) (Fig. 4B). Together these data suggest that activation
of DA D1 receptors in the mPFC during encoding impairs
object discrimination using a delay of 10 min.
3.5. Experiment 5: systemic injections of
SKF81297 and locomotor activity
SKF81297 markedly increased locomotor activity in the
activity boxes (Fig. 5). In the 30 min preceding the injection
of saline or SKF81297 (0.4 and 0.8 mg/kg), the different
infusion groups showed similar locomotor activity. There
was no main effect of treatment: (F(2,33)=0.55; p=0.56)
nor any interaction of treatment 10 min time bin (F(4,66)
=2.22; p=0.07). Systemic administration of SKF81297
increased activity at all doses compared to saline starting
10 min after injection and lasting for about 50 min. There
was both a main effect of treatment (F(2,33)=15.9;po0.0001) and an interaction of treatment 10 min bin (F
(10,165)=6.41; po0.0001). Separate ANOVAs and post-hoc
comparisons of locomotor activity during the 6 10-min
blocks revealed that, compared to saline, 0.4 and 0.8 mg/
kg SKF81297 did not increase locomotor activity during the
ﬁrst 10-min bin (F(2,33)=1.68; p=0.20) whereas groups
differed during the other 10-min bins (all F410.85;
po0.002; post-hoc tests, po0.05).3.6. Experiment 6: infusion of SKF81297 into the
mPFC and locomotor activity
SKF81297 infusion into the mPFC did not affect locomotor
activity in the activity boxes (Fig. 6). The different infusion
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Figure 5 Effect of systemic injections of SKF81297 on sponta-
neous activity. The rats were habituated to the activity
chambers for 30 min before being injected with saline,
SKF81297 0.4 or 0.8 mg/kg of SKF81297. Locomotor activity
was then monitored for an additional 60 min. Data are pre-
sented as mean7S.E.M. (n=12 rats per group). Asterisks
indicate a signiﬁcant difference as compared to saline with
**po0.001, ***po0.0001.
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Figure 6 Effect of PL infusion of SKF81297 on spontaneous
activity. The rats were habituated to the activity chambers for
30 min before being injected with saline (n=4), 0.025 (n=3) or
0.05 μg/side (n=4) of SKF81297. Locomotor activity was then
monitored for an additional 60 min. Data are presented as
mean7S.E.M.
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preceding the infusion of saline or SKF81297 (0.025 or
0.05 μg/side). There was no main effect of treatment (F
(2,8)o1) nor any interaction of treatment 10 min bin: (F
(4,16)o1). Following infusion there was still no main effect
of treatment (F(2,8)o1) or interaction of treatment 10
min bin (F(10,40)o1).3.7. Histology
No gross damage was seen after drug infusion, and the
morphological structure of the mPFC was preserved
(Fig. 7A). Fig. 7B shows reconstructed injector tip place-
ments which were between 2.7 and 4 mm anterior tobregma in in the PL region of the mPFC according to the
atlas of Paxinos and Watson (1998).
4. Discussion
Systemic (s.c.) administration of the D1 receptor agonist
SKF81297 before encoding impaired NOR at the lowest dose
after a delay of 10 min. Both doses of SKF81297 (s.c.)
decreased NOR encoding and retrieval after a delay of
24 h. Both doses of SKF81297 (s.c.) stimulated locomotor
activity. In experiment 4, we used a 10 min delay to show
that intra-mPFC infusion of SKF81297 induced a dose-
related impairment in encoding and/or retrieval. Both
overall object exploration and locomotor activity were
unaffected by this manipulation. Thus the present study
shows that DA D1 receptor activation modulates the forma-
tion and expression or retrieval of visual recognition mem-
ory and that this effect is, at least in part, mediated in
mPFC. In contrast, the effects of DA D1 receptor activation
on general levels of activity and exploration are not
necessarily mediated in mPFC.
4.1. Effect of DA D1 receptor stimulation on
locomotor activity and exploration
Increased locomotor activity after s.c. administration of the
D1 receptor agonist SKF81297 is consistent with previous
reports (Arnt et al., 1992). Similarly,intra-mPFC infusion of
SKF81297 has previously been reported to be without effect
on locomotor activity (Sorg et al., 2004). Independent
evidence suggests that the increased locomotor activity
observed after s.c. administration of SKF81297 may have
been induced by its stimulating effect on accumbal and/or
striatal D1 receptor-mediated transmission (Cools et al.,
2002; Diaz Heijtz and Castellanos, 2006).
General locomotor activity levels do not necessarily
predict object exploration. As can be seen from comparison
of the saline groups, there were different baseline levels of
exploration, but each experiment controls for these unex-
plained shifts (sometimes particular batches of animals are
more or less exploratory for reasons which are poorly
understood, and with respect to the objects used some
are found to be more salient). Also in both experiments
1 and 2, D1 receptor stimulation decreases object explora-
tion (as measured during the sampling phase). It could be
argued that the NOR memory deﬁcits observed relate to this
reduction in exploratory encoding of the object to be
remembered. In experiment 1 however, only the lowest
dose of SKF81297 impaired memory, whereas (during the
sampling phase) object exploration was decreased at both
doses. If reduced sample exploration caused the apparent
NOR impairment, both doses should have decreased NOR. In
experiment 3, SKF81297 also decreased exploration of both
the familiar and the novel object when injected before the
test phase, possibly reﬂecting some locomotor effects.
However the difference between the exploration times of
the novel and familiar objects so clearly present in the
saline group was absent after injection of SKF81297. More-
over, the pattern of results seen in experiment 1 shows that
deﬁcits in NOR are dissociable from non-speciﬁc locomotor
effects.
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Figure 7 Infusion cannulae placement. (A) Cresyl-violet-stained section showing an example of PL infusion site. (B) Approximate
locations of infusion cannula tips (dots) in the PL subdivision of the mPFC. Locations are shown on coronal plates adapted from
Paxinos and Watson (1998), with numbers indicating distance anterior from bregma in millimetres.
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encoding of NOR
Although DA has been implicated in recognition memory
processing, its role in the different stages of this process –
(encoding versus retrieval/expression) remain poorly under-
stood. The results of experiments 1 and 2 show that
SKF81297 impaired NOR when injected prior to the sampling
phase and after a delay of 10 min and 24 h. At a short delay,
it is impossible to discriminate whether memory formation
or retrieval has been affected, the drug being effectively
active in the brain during both processes. However, the
persistence of the impairment after a delay of 24 h implies
that the formation of a familiar memory is dependent on D1
receptor activation. Importantly, consolidation, which
refers to a category of processes that stabilise a memory
trace after its initial acquisition, has been demonstrated to
be dependent on D1 receptor activation (de Lima et al.,
2011). It is therefore possible that in experiments 1 and
2 the drug may have interfered with consolidation. That D1
receptor transmission may play a key role in NOR is in line
with previous studies suggesting the importance of DA D1
receptor activation in different forms of memory (El-Ghundi
et al., 2007) and memory encoding in particular (O'Carroll
et al., 2006; Pezze and Bast 2012). Interestingly, NOR has
been shown to rely on plasticity (Bussey et al., 1999; Brownand Aggleton, 2001) and the positive modulation by D1
receptor induction and maintenance of long-term potentia-
tion (LTP) is well characterised (Jay, 2003; Huang et al.,
2004; El-Ghundi et al., 2007). It has also been shown that a
too much stimulation of the D1 receptor by SKF81297
increases signalling mediated by mTOR, a protein kinase
involved in long lasting synaptic plasticity (Gangarossa
et al., 2014;). Too much mTOR stimulation also blocks LTP
and impairs long term recognition memory (Gangarossa
et al., 2014). Together these ﬁndings suggest that the
encoding of NOR memory may rely on the modulation of
LTP by an optimal level of stimulation of the D1 receptor
subtype. Our previous data showed that the D3 receptor
antagonist S33084 alleviates the NOR deﬁcit induced by
social isolation (Watson et al., 2012a, 2012b). Our present
results do not preclude the possibility that an appropriate
dose of the D1 receptor agonist SKF81297 may act as a
cognitive enhancer (Floresco and Phillips 2001, Pezze et al.,
2007; see also below).4.3. Effects of DA D1 receptor stimulation on the
retrieval of NOR
Besheer et al. (1999) have shown that systemic injection of
the DA receptor antagonist SCH23390 before the retention
M.A. Pezze et al.2154test impaired performance of rats in detecting a novel
object, suggesting an effect on retrieval. Hotte et al. (2005)
reported that D1 receptor stimulation decreased NOR
retrieval after a delay of 15 min. The present study
conﬁrmed that a similar dose of SKF81297 decreased
performance after a delay of 10 min. However, the above
study also reported enhanced retrieval after a long delay
(Hotte et al., 2005), whereas the present results showed
impairment NOR after a delay of 24 h. This may be related
to procedural differences. First, in the present study, the
animals were habituated to the empty arena on one
occasion for one hour, whereas in the study of Hotte and
co-workers, the habituation took place over 5 days in blocks
of 3 to 10 min. Second, in our experiment the rats had 5 min
to sample the objects compared to 3 min in the study by
Hotte et al. (2005). Third, strain differences may have
contributed to the different ﬁndings (Sprague–Dawley vs.
Wistar rats). Thus, while SKF81297 clearly impairs NOR
retrieval at a short retention delay of 10 min, the effects
at longer retention delay of several hours are less clear cut.4.4. Effects of DA D1 receptor stimulation in the
PL mPFC on NOR memory
Pre-sampling infusions of SKF81297 into the PL part of the
mPFC impaired NOR memory after a delay of 10 min without
affecting activity or exploration. This suggest an involve-
ment of D1 receptor activation in the formation and or
retrieval/expression of NOR. Clausen et al. (2011) also
reported a decrease in recognition memory after mPFC
micro-infusion of the DA D1 receptor antagonist SCH23390.
At ﬁrst glance, these two set of data appear to be at odds
with reports that excitotoxic lesions of the mPFC
(Hannesson et al., 2004) and catecholaminergic depletion
in the PL mPFC (Nelson et al., 2011) do not impair the
standard NOR test in rodents. The lack of effect of these
lesions may have been due to their incompleteness. In
addition, permanent lesions, in contrast to temporary
pharmacological blockade by drug microinfusion, may elicit
compensatory process that lead to recovery of function
(Bast and Feldon, 2003). In any event, negative results with
lesions do not exclude a neuromodulatory role (Cassaday
et al., 2014).
Together with Clausen's data, our results demonstrate
that PL D1 receptor function is involved in non-spatial
recognition memory (Clausen et al., 2011). The ﬁnding that
both the D1 receptor antagonist SCH23390 (Clausen et al.,
2011) and the agonist SKF81297 impaired NOR memory when
infused into the PL may reﬂect an inverted U-shaped
function relating the formation or retrieval/expression of
NOR memory to DA-receptor stimulation in the mPFC.
Similarly, working memory, attention and conditioned fear
retrieval have also been suggested to require an optimal
level of prefrontal DA-receptor stimulation (Williams and
Goldman-Rakic, 1995; Arnsten, 1998; Robbins, 2000; Pezze
et al., 2003).
Floresco and Phillips (2001) reported that activation of D1
receptors in the mPFC disrupts memory retrieval when
performance is strengthened by a short delay. Interestingly,
it has also been shown that impaired NOR retrieval by
systemic injection of SCH23390 is correlated with decreasedphosphorylation of cAMP response element binding protein
(CREB) within the PFC (Hotte et al., 2006). Similarly, in
conditioning procedures, Pezze et al. (2003) showed that
the retrieval/expression but not formation of a conditioned
emotional response (CER) relies on DA in the mPFC.
Furthermore, it is also known that D1 receptor activation
inﬂuences CER retrieval only (Lauzon et al., 2009). In the
present study, infusions of SKF81297 in the PL sub-region of
the mPFC before sampling impaired performance when
tested 10 min later. Thus the drug was effective during both
the encoding as well as the retrieval/expression phase of
NOR and there was no clear dissociation between the
memory stages. However, taken together with the results
of the studies discussed above, impaired memory retrieval
may be the major determinant of D1 receptor-induced NOR
deﬁcits.5. Conclusions
The results of the present study show that DA D1 receptor
activation modulates not only retrieval/expression, but also
encoding in the NOR procedure. In addition, the results
demonstrate that D1 receptor transmission within the PL
part of the mPFC is important for NOR memory. The effects
of prefrontal D1 receptor stimulation revealed in the pre-
sent study resemble those reported following prefrontal D1
receptor antagonism in previous studies. Therefore, we
propose that NOR memory requires an optimal level of D1
receptor stimulation in the mPFC.Role of funding source
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